Salt Lake City, Utah-based ZARS, a developer of pharmaceuticals, said in a filing with the SEC Thursday that it will offer 5,000,000 shares of its common stock at between $14.00 and $16.00 in an IPO on the NASDAQ. ZARS is looking to list under the symbol ZARS on the NASDAQ Global Market. The firm is venture backed by Draper Fisher Jurvetson, Wasatch Ventures, vSpring Capital, and others. The firm's IPO is being underwritten by Cowen and Company, CIBC World Markets, Leerink Swann & Company, and Susquehanna Financial. ZARS specializes in the development and commercialization of topically applied drugs.